Zydus Cadila has received a tentative approval for Dimethyl Fumarate Delayed-Release Capsules, 120 mg and 240 mg (US RLD TECFIDERA capsules).
It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. Dimethyl Fumarate is indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)